Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 2/20 | 0.64 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.64 |
| ▸ | CDK1 | P06493 | 2/20 | 0.64 |
| ▸ | CDK4 | P11802 | 2/20 | 0.64 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.64 |
| ▸ | CCND1 | P24385 | 2/20 | 0.64 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.64 |
| ▸ | CDK2 | P24941 | 2/20 | 0.64 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2481820 | 0.92 | CCNB2 (0.56) | CCNB2CCNE2CDK1CDK4CCNB1 | |
| SCHEMBL999731 | 0.86 | SMN1; SMN2 (0.56) | CCNB2CCNE2CDK1CDK4CCNB1 | |
| SCHEMBL2656865 | 0.85 | CDK2 (0.49) | CCNB2CCNE2CDK1CDK4CCNB1 | |
| SCHEMBL16086613 | 0.83 | SMN1; SMN2 (0.53) | CCNB2CCNE2CDK1CDK4CCNB1 | |
| SCHEMBL2650788 | 0.79 | SMN1; SMN2 (0.48) | CCNB2CCNE2CDK1CDK4CCNB1 | |
| SCHEMBL735616 | 0.78 | SMN1; SMN2 (0.47) | CCNB2CCNE2CDK1CDK4CCNB1 | |
| SCHEMBL2606389 | 0.78 | MYC (0.44) | CCNB2CCNE2CDK1CDK4CCNB1 | |
| SCHEMBL997925 | 0.77 | ALDH1A1 (0.61) | CCNB2CCNE2CDK1CDK4CCNB1 | |
| SCHEMBL19018619 | 0.76 | HSP90AB1 (0.44) | CCNB2CCNE2CDK1CDK4CCNB1 | |
| SCHEMBL1241542 | 0.75 | SMN1; SMN2 (0.50) | CDK1CDK4CCNE1CDK2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2931718-B1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | MERCK SHARP & DOHME (US) | 2019-01-16 | — | — | EP | disclosed |
| US-9527838-B2 | 2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527838-B2 | 2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20150336946-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150336946-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | US | disclosed |
| EP-2099777-B1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK AS (DK) | 2015-08-12 | — | — | EP | disclosed |
| EP-2099777-B1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK AS (DK) | 2015-08-12 | — | — | EP | disclosed |
| US-8921576-B2 | Spiroindoline compound, and medicinal agent comprising same | KOWA COMPANY, LTD. (JP) | 2014-12-30 | — | — | US | disclosed |
| US-20140309207-A1 | NOVEL SPIROINDOLINE COMPOUND, AND MEDICINAL AGENT COMPRISING SAME | KOWA COMPANY, LTD (JP) | 2014-10-16 | — | — | US | disclosed |
| US-RE45183-E1 | Heteroaryl-ureas and their use as glucokinase activators | NOVO NORDISK A/S (DK) | 2014-10-07 | — | — | US | disclosed |
| US-20070027140-A1 | N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes | NOVO NORDISK A/S (DK) | 2007-02-01 | — | — | US | disclosed |
| WO-2007006761-A1 | DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007006760-A1 | DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007006814-A1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
| EP-1723128-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2006-11-22 | — | — | EP | disclosed |
| EP-1689392-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2006-08-16 | — | — | EP | disclosed |
| WO-2006058923-A1 | HETEROAROMATIC GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2006-06-08 | — | — | WO | disclosed |
| WO-2005066145-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005049019-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2005-06-02 | — | — | WO | disclosed |
| US-4006127-A | Cationic diazacyanine dyestuffs | BAYER AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336946-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | GCK, HK2, GCKR | CCNB2 3579/4885CCNE2 3696/4885CDK1 1282/4885 |
| US-20070027140-A1 | N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes | GALK1, GCKR, GCK | CCNB2 1737/4885CCNE2 1579/4885CDK1 908/4885 |
| US-20140309207-A1 | NOVEL SPIROINDOLINE COMPOUND, AND MEDICINAL AGENT COMPRISING SAME | GCKR, GCK, GALK1 | CCNB2 3121/4885CCNE2 1668/4885CDK1 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.